Form D · Pharmaceuticals
BrainCells Inc
San Diego, CA · CIK 0001313096
Offering snapshot reported Oct 26, 2012 · SEC filing
- Reported sold
- $4.1M Offering amount: $9M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 29, 2011 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$1,978,046 → $4,100,000
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 26, 2012 | Amendment | $4,100,000 | $2,121,954vs Jan 11, 2012 | 5 | SEC filing |
| Jan 11, 2012 | Initial | $1,978,046 | No comparison | 5 | SEC filing |
| Aug 1, 2011 | Initial | $994,727 | No comparison | 7 | SEC filing |
| Mar 31, 2009 | Initial | $135,000 | No comparison | Not reported | SEC filing |
| Nov 25, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jul 18, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Mar 10, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 19, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 12, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 29, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 12, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-171611
Total Offering Amount includes estimated amounts receivable by the Issuer upon exercise of certain warrants to purchase the Issuer's Preferred Stock; such warrants have not yet been exercised.
Source: Form D, filed Oct 26, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Carolee Barlow | Executive |
| Ellen Baron | Director |
| William C. Bertrand | Director |
| Fred H. Gage | Director |
| Carl Goldfischer | Director |
| Harry F., Jr. Hixson | Director |
| Philip Jochelson | Executive |
| Jason D. Levin | Executive |
| Alana B. Mc Nulty | Executive |
| V. Ray Nathan | Executive |
| Charles W. Iii Newhall | Director |
| Arthur Pappas | Director |
| Roger J. Quy | Director |
| James A. Schoeneck | Director, Executive |
| David Thompson | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
3636 Nobel Drive Suite 215
San Diego, CA, 92122
San Diego, CA, 92122